Skip to main content
Fig. 4 | Arthritis Research & Therapy

Fig. 4

From: Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: a randomized, controlled trial

Fig. 4

ACR20, ACR50, and ACR70 at week 12 (per-protocol set). Significant p values compared to placebo are shown by an asterisk (ACR20 for 20 mg, p = 0.031, and ACR50 for 150 mg, p = 0.049). ACR American College of Rheumatology, ACR20 ≥ 20% improvement, ACR50 ≥ 50% improvement, ACR70 ≥ 70% improvement, PBO placebo

Back to article page
\